January 27, 2021

Nifty Outlook

Markets traded volatile and lost nearly a percent, in continuation to the prevailing corrective phase. The benchmark opened on a firm note following positive global cues however it pared all its gains no time and hovered range-bound thereafter. Dometic cues viz. decline in index major, Reliance, post the results and news of fresh feud between India-China at Sikkim border dented the sentiment. Finally, the Nifty index ended lower by 0.9% at 14,238.9 levels. On the sector front, except healthcare and metals, all the other indices ended with losses wherein Oil & Gas, IT and Auto were the top losers. The broader indices were trading under pressure from the beginning and lost in the range of 1.2% each.

It's a holiday-shortened week and we expect volatility to remain high ahead also due to the scheduled expiry of January month derivatives contracts. Besides, we're seeing participants speculating on the probable announcements in the Union Budget, which is further adding to the volatility. Amid all, we reiterate our view that a decisive close below 14,200 in Nifty would derail the present momentum so participants should align their positions accordingly.

	VWAP (Expiry till date)	Max OI (Call)	Max OI (Put)
NIFTY	13950	15000	14000
Nour			

News

- Mahindra Holidays reported its numbers wherein revenue was down 16.8% YoY to Rs. 489 cr. Its net profit came in at Rs. 0.2 cr as against Rs. 5 cr YoY.
- **PNC Infratech** announced it has received Letter of Award for 6 new EPC for Projects Survey, Design, Preparation of DPR, Construction, Commissioning and O&M for l0 years of Rural Water Supply.
- Kotak Mahindra Bank reported 16.1% YoY growth in net profit which came in at Rs. 1,854 cr. The NII grew by 16.8% YoY to Rs. 4,007 cr.





Religare Super Idea**										
Scrip	Buy/Sell	СМР	Initiation Range	SL*	Target					
ESCORTS	SELL FEB FUTS	1225.40	1240-1250	1285	1160					

**Please note that the given technical and derivative recommendations are "valid for taking position" only on recommended date and in the given range.

*Please note - Stoploss is on closing basis for delivery recommendation and intraday basis for F/O recommendation.

Derivative	Derivative Ideas **					Sectors to watch		FII & DII Cash Segment (Rs. in Cr.)				Trade Stats		
Instrument	B/S	Lot	INITIATION RANGE	SL	TARGET	Sector Name	Outlook	Category	Amt.	MTD	FYTD		NO OF CONTRACTS	TURNOVER IN CR
						ІТ	BULLISH	FII**	-635	-21077	170173	IDXFUTS	546588	50054
									000			IDXOPT	33300559	16592
CADILAHC	BUY	CASH	460-462	450	476	BANKS	BULLISH	DII**	-1290	-15759	-125232	STKFUTS	1926757	160320
						FMCG	BULLISH	**Provision	al data as	on 22 nd Ja	nuary, 2021			

January 27, 2021



Derivative Ideas

CADILAHC FEB FUT added around 34% in open interest addition as LONG buildup was seen in it in till closing time. Current chart pattern also indicates further up move in its price. We suggest buying CADILAHC as per below levels.

Strategy:- BUY CADILAHC BETWEEN 460-462 SL 450 TARGET 476.

Investment Pick - SBI Life Insurance Company Ltd.									
Scrip	СМР	Recommendation Price	Target	Duration					
SBI Life Insurance Company Ltd.	862.85	874	1,069	9-12 Months					

• SBI Life Insurance Company Ltd. is a joint venture between State Bank of India and BNP Paribas Cardiff S.A. It is one of the leading life insurers in India with a healthy market share of 13.3% in terms of Individual rated premium. SBI Life offers a comprehensive range of life insurance and pension products at competitive prices, ensuring high standards of customer service and world-class operating efficiency.

• Within the industry, SBI Life is one of our preferred picks given its huge untapped client base, wide distribution reach and industry-leading cost ratios. Further, increased focus on business through digital channels and a strong distribution platform should lead to consistent market share gains for the company. We initiate with a Buy rating on the stock with a target price of Rs. 1069.

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	25	26	27	28	29	30
			• Dcm Shriram Limited	• Gmm Pfaudler Ltd.	• Srf Ltd.	
			• Gail (India) Ltd.	• Havells India Ltd.	• Zensar Technologies Ltd.	
			India Grid Trust	Indian Energy Exchange Ltd		
			• Siemens Ltd.			

January 27, 2021

Result Calendar - January 2021



Mon	Tue	Wed	Thu	Fri	Sat
 Aarti Drugs Ltd. Apl Apollo Tubes Ltd. Icici Securities Ltd Kotak Mahindra Bank Ltd. 	Tue 26	Wed 27 • Axis Bank Ltd. • Bank Of Baroda • Canara Bank • Emami Ltd. • Hindustan Unilever Ltd.	Thu 28 • Aarti Industries Ltd. • Alembic Ltd. • Angel Broking Ltd • Au Small Finance Bank Ltd • Bharat Electronics Ltd.	Fri 29 • Adf Foods Ltd. • Atul Ltd. • Blue Star Ltd. • Cipla Ltd. • Dabur India Ltd.	 Amber Enterprises India Ltd Bcpl Railway Infra- structure Ltd Icici Bank Ltd. Relaxo Footwears Ltd
 Larsen & Toubro Ltd. Navin Fluorine Inter- national Limited Uco Bank 		 Icici Prudential Life Insurance Company Ltd India Cements Ltd. Marico Ltd. Nippon Life India Asset Management Ltd Tata Coffee Ltd. Welspun India Ltd. 	 Blue Dart Express Ltd. Colgate-Palmolive (India) Ltd. Cummins India Ltd. Granules India Ltd. Ifb Industries Ltd. Interglobe Aviation Ltd Indian Railway Catering And Tourism Corporation Ltd Kei Industries Ltd. Kpit Technologies Ltd 	 Dr.Reddy'S Laboratories Ltd. Exide Industries Ltd. Jk Lakshmi Cement Ltd. Kaya Ltd Dr. Lal Pathlabs Ltd Paushak Ltd. Subros Ltd. Upl Limited Uti Asset Management Company Ltd 	• Shree Cement Ltd.

For complete schedule of more Company Results Calendar <u>click here</u>.

CACT Ca	CACT Calendar - January 2021 (E.G.M.)										
Sun	Mon	Tue	Wed	Thu	Fri	Sat					
24	25	26	27	28Shree Rama Multi-Tech Ltd.	29	30					

CACT Calendar - January 2021 (Buy Back of Shares)											
Sun	Mon	Tue	Wed	Thu	Fri	Sat					
24	25	26	27	28	29	30					
			• Gail (India) Ltd.								

CACT	CACT Calendar - January 2021 (Right Issue of Equity Shares)									
Sun	Mon	Tue	Wed	Thu	Fri	Sat				
24	25	26	27	28	29	30				
			Emerald Leasing Finance & Investment Company Ltd							

January 27, 2021

Religare Investment Calls



Religate investment Calls								
Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	СМР	Expected returns from CMP %
Cummins India	31-Jan-2020	Buy	Investment Call	585	705	20.5%	611	15.5%
Godrej Agrovet	13-Feb-2020	Buy	Investment Call	559	618	10.5%	545	13.3%
INOX Leisure	20-Aug-2020	Buy	High Conviction Ideas	282	376	33.3%	313	20.2%
Godrej Consumer Products	16-Sept-2020	Hold	Investment Call	706	845	19.7%	779	8.4%
Britannia Industries	22-Oct-2020	Buy	High Conviction Ideas	3,397	4,265	25.5%	3,614	18.0%
Castrol India	02-Nov-2020	Buy	Investment Call	114	151	32.5%	128	17.9%
Bharti Airtel	09-Nov-2020	Buy	High Conviction Ideas/ Diwali Picks	450	709	57.6%	581	22.1%
Nippon Life India Asset Management	09-Nov-2020	Buy	Diwali Picks	285	348	22.1%	314	10.8%
Sudarshan Chemical Industries	09-Nov-2020	Buy	Diwali Picks	442	583	31.9%	500	16.6%

*Current rating is based on returns potential

Buy - Potential Returns **>10%** over 12 months **Hold** - Potential Returns **<10%** over 12 months

For Religare Investment calls performance <u>click here</u>

January 27, 2021

Religare Investment Calls



Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	СМР	Expected returns from CMP %
ітс	19-Nov-2020	Buy	Investment Call	190	238	25.3%	208	14.5%
Dabur India	24-Nov-2020	Buy	High Conviction Ideas	509	616	21.0%	533	15.7%
Axis Bank	28-Dec-2020	Hold	New Year Picks 2021	610	721	18.2%	658	9.5%
Coromandel International	28-Dec-2020	Buy	New Year Picks 2021	802	978	21.9%	840	16.4%
IRCTC	28-Dec-2020	Buy	New Year Picks 2021	1,409	1,755	24.6%	1,426	23.0%
JK Lakshmi Cement	28-Dec-2020	Buy	New Year Picks 2021	337	428	27.0%	326	31.5%
Mahindra and Mahindra	28-Dec-2020	Buy	New Year Picks 2021	711	889	25.0%	795	11.9%
Manappuram Finance	28-Dec-2020	Buy	New Year Picks 2021	164	205	25.0%	160	27.9%
Natco Pharma	28-Dec-2020	Buy	New Year Picks 2021	932	1,135	21.8%	894	26.9%
SBI Life Insurance	28-Dec-2020	Buy	New Year Picks 2021	874	1,069	22.3%	863	23.9%

*Current rating is based on returns potential

Buy - Potential Returns **>10%** over 12 months **Hold** - Potential Returns **<10%** over 12 months

For Religare Investment calls performance <u>click here</u>

January 27, 2021

Research Product Basket

- For every client, the advisor must allocate a specific proportion of funds for trading and investing depending on the risk taking ability and willingness of the client and their investment goals.
- The below mentioned product basket tries to address the way to deal with the trading portfolio (cash/derivative) for optimum effectiveness of research calls.
- It is recommended to divide your trading funds for various types of calls and not invest the entire amount for 1 or 2 calls only.

		For cash	market trading		For 1L m	argin*				
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated	Total	Per Call				
Intraday Calls	Intraday	2 - 3	< 1 day	25%	25,000	8,000				
Live / RMD Calls	Daily	3 - 4	3 - 4 days	30%	30,000	4,000				
Master Pick	Weekly	1	1 month	15%	15,000	5,000				
Religare Alpha	Opportunity	NA	2 - 3 months	20%	20,000	As per weightage				
Cash		NA		10%	10,000					
Intraday Calls	These calls are flashed live on Ms Lync and ODIN with the purpose of squaring off positions on the same day. As a policy, we restrict our intraday cash market calls to less than 4 calls a day. Hence, funds should be allocated accordingly to have provision to trade in all calls.									
Live / RMD Calls		lls). 3-4 such call	s are made on a daily basis	days. Additionally as per market opp which might be open for 3-4 days. Fun						
Master Pick	-			f techno-funda analysis. 15% of funds pen duration for this call will be 1 mon		llocated for Master				
Religare Alpha	•		hich are held with a view of overall trading portfolio.	2-3 months. It is recommended to allo	cate 20% of funds for bu	ilding this portfolio				
Cash	10% surplus cash i	n the portfolio s	hould be kept for the purpo	oses of allocating it to opportunities as	and when they arrive.					

For derivative market trading				For 1L margin*		
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated	Total	Per Call
Derivative Ideas	Daily	1 - 2	1 - 3 days	40%	40,000	40,000
Live calls	Intraday / Daily	1 - 2	3 - 4 days	50%	50,000	50,000
Cash		NA		10%	10,000	
Derivative Ideas	1 derivative idea is shared in RMD daily. It can be a plain vanilla F&O buy/sell call or an option strategy. Funds should be allocated assuming 2 such calls will be open at any time. These calls are open for 3-4 days on an average.					
Live Calls	These calls are flashed on MS Lync and ODIN during live market hours. These calls can be intraday or with a view of 2-3 days. Funds should be allocated considering 2 such calls will be open at any time. 3/4 times, these calls will be on Nifty / Bank Nifty only.					
Cash	It is recommended to hold 10% cash to capitalize on any opportunity that may arise in markets.					



January 27, 2021



Research Analysts

Ajit Mishra	ajit.mishra@religare.com
Himanshu Sharma	himanshu.sharma1@religare.com
Manoj M Vayalar	manoj.vayalar@religare.com
Nirvi Ashar	nirvi.ashar@religare.com
Rohit Khatri	rohit.khatri@religare.com
Suhanee Shome	suhanee.shome@religare.com

January 27, 2021



Before you use this research report , please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest , compensation– Research Analyst (RA)

[Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) below , are given separately]

S. No.	Statement		Answer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	

I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?	No
I/we have received any compensation from the subject company in the past twelve months?	No
I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?	No
I/we have received any compensation for brokerage services from the subject company in the past twelve months?	No
I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?	No

	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?	No
	I/we have served as an officer, director or employee of the subject company?	No
	I/we have been engaged in market making activity for the subject company?	No

Nature of Interest (if answer to F (a) above is Yes :

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) above , are given below]

SSNo.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No.

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results